Franklin Resources Inc. Has $31.50 Million Stock Holdings in Illumina, Inc. (NASDAQ:ILMN)

Franklin Resources Inc. lowered its position in shares of Illumina, Inc. (NASDAQ:ILMN) by 22.5% in the third quarter, Holdings Channel reports. The firm owned 241,507 shares of the life sciences company’s stock after selling 70,305 shares during the period. Franklin Resources Inc.’s holdings in Illumina were worth $31,495,000 at the end of the most recent quarter.

Several other large investors have also recently bought and sold shares of the company. Industrial Alliance Investment Management Inc. bought a new position in shares of Illumina during the second quarter worth $34,000. TD Private Client Wealth LLC increased its position in shares of Illumina by 58.5% in the 3rd quarter. TD Private Client Wealth LLC now owns 382 shares of the life sciences company’s stock valued at $50,000 after buying an additional 141 shares in the last quarter. Massmutual Trust Co. FSB ADV raised its stake in Illumina by 65.1% during the 3rd quarter. Massmutual Trust Co. FSB ADV now owns 426 shares of the life sciences company’s stock worth $56,000 after buying an additional 168 shares during the period. Private Trust Co. NA lifted its holdings in Illumina by 81.2% during the third quarter. Private Trust Co. NA now owns 473 shares of the life sciences company’s stock worth $62,000 after acquiring an additional 212 shares in the last quarter. Finally, Focused Wealth Management Inc acquired a new position in Illumina in the third quarter valued at about $63,000. Institutional investors own 89.42% of the company’s stock.

Illumina Trading Down 6.4 %

NASDAQ ILMN opened at $134.03 on Thursday. The company has a market cap of $21.26 billion, a PE ratio of -13.46 and a beta of 1.11. Illumina, Inc. has a 12 month low of $100.08 and a 12 month high of $156.66. The stock has a 50 day moving average of $144.30 and a 200-day moving average of $129.24. The company has a current ratio of 2.43, a quick ratio of 1.85 and a debt-to-equity ratio of 0.94.

Illumina (NASDAQ:ILMN) last announced its quarterly earnings data on Monday, November 4th. The life sciences company reported $1.14 EPS for the quarter, beating analysts’ consensus estimates of $0.88 by $0.26. The company had revenue of $1.08 billion during the quarter, compared to the consensus estimate of $1.08 billion. Illumina had a negative net margin of 36.10% and a positive return on equity of 7.29%. The company’s quarterly revenue was down 3.5% on a year-over-year basis. During the same quarter last year, the firm posted $0.33 EPS. On average, equities research analysts anticipate that Illumina, Inc. will post 4.11 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently commented on ILMN shares. Stephens raised their price target on Illumina from $170.00 to $184.00 and gave the stock an “overweight” rating in a research report on Tuesday, November 12th. Citigroup lowered shares of Illumina from a “buy” rating to a “neutral” rating and cut their price target for the company from $190.00 to $165.00 in a research note on Wednesday, December 11th. Morgan Stanley reiterated an “equal weight” rating and issued a $156.00 price target on shares of Illumina in a report on Tuesday, November 12th. Argus upgraded shares of Illumina from a “hold” rating to a “buy” rating and set a $150.00 price objective on the stock in a report on Wednesday, August 28th. Finally, JPMorgan Chase & Co. boosted their price objective on shares of Illumina from $125.00 to $140.00 and gave the company a “neutral” rating in a research report on Tuesday, November 5th. Eight equities research analysts have rated the stock with a hold rating, eleven have assigned a buy rating and two have issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Illumina presently has a consensus rating of “Moderate Buy” and an average target price of $165.95.

Illumina Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.